Quest Diagnostics Stock News

In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.

In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.

The U.S. daily death toll from COVID-19 rose to its highest level since last winter's peak on Tuesday, according to a New York Times tracker and other sources, after the surge in cases in December and

Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.

Quest Diagnostics (DGX) announces the availability of an at-home COVID-19 rapid antigen test service for consumer purchase, available through QuestDirect, the company''s

Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.

On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.

With growing concerns about stability inducing significant fear, contrarians may have an opportunity with undervalued stocks. The post 7 Undervalued Stocks That Won't Stay That Way for Long appeared f

Duopoly lab operator Quest Diagnostics was the only stock to meet each parameter of my stock picking checklist for fundamentals, value, and risk. The stock's price accelerated at the beginning of the

Quest Diagnostics (DGX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es

Quest Diagnostics (DGX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es

The stock price of Quest Diagnostics, one of the largest U.S. diagnostics chains, has seen a fall of 15% over the last twenty-one trading days, while it is up 5% over the last week. The recent fall ca

This latest acquisition builds on Quest Diagnostics' (DGX) 2018 acquisition of Mobile Medical Examination Service (MedXM), a provider of home-based health risk assessments and related services.

Average daily attendance of 565 in 2022 versus 346 in 2021 Over 4,000 registrants with attendees represented from 82 countries 31 oral presentations delivered across four consecutive days 37 scientific posters featuring OGM in the online exhibit hall On-demand presentations from Symposium available for remainder of 2022 SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of N x Clinical, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the conclusion of Bionano''s 2022 Symposium, with record daily attendance representing a 63% increase relative to last year''s event. Bionano''s premier scientific event showcasing OGM, Symposium was held January 10-13, 2022. Symposium had over 4,000 registrants from 82 countries and featured 31 oral presentations and 37 scientific posters from genomic scientists at leading institutions, including Brigham and Women''s Hospital, MD Anderson Cancer Center, and Quest Diagnostics.